Brief: XBiotech Inc Plans To Seek FDA Guidance Based On Phase III Studies In Oncology Findings
Oct 31 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH INC - PLANS TO SEEK FDA GUIDANCE BASED ON PHASE
III
STUDIES IN ONCOLOGY FINDINGS
* XBIOTECH - INCREASING OUTPUT CAPACITY FOR SYRINGES WITH
TARGET
ANNUAL PRODUCTION CAPACITY OF ABOUT 300,000 UNITS BY 2019
Source text for Eikon: ID:nGNX5tldgD
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke